Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer

Evexta Bio SA provided an update on the clinical development of its lead asset, rupitasertib, a selective oral inhibitor of S6K and AKT1/AKT3.